Keyphrases
In Cancer
100%
Urokinase-type Plasminogen Activator
100%
Tumor Metastasis
100%
Urokinase Plasminogen Activator System
100%
Tumor Angiogenesis
100%
Soluble Urokinase Plasminogen Activator Receptor (suPAR)
75%
Angiogenesis
25%
Leukocytes
25%
Receptor System
25%
Tumor Cells
12%
Metastasis
12%
Therapeutic Agents
12%
Plasminogen Activator inhibitor-1 (PAI-1)
12%
Cell Biology
12%
Endothelial Cells
12%
Growth Factors
12%
Patient Outcomes
12%
Tumor
12%
Invasiveness
12%
Expression Level
12%
Therapeutic Target
12%
Oncogene
12%
Neovascularization
12%
Differentiation Factors
12%
Patient Prognosis
12%
Substantial Evidence
12%
Solid Tumors
12%
Receptor Targets
12%
Antiangiogenic
12%
Therapeutic Implications
12%
Prognostic Implications
12%
Differentially Expressed
12%
Antimetastatic
12%
Quiescent Cells
12%
Motile Cells
12%
Medicine and Dentistry
Urokinase
100%
Metastatic Carcinoma
100%
Tumor Angiogenesis
100%
Malignant Neoplasm
100%
Urokinase Receptor
85%
Receptor
28%
Angiogenesis
28%
Leukocyte
28%
Neoplasm
14%
Cytotechnology
14%
In Vitro
14%
Therapeutic Agent
14%
Diagnosis
14%
Tumor Cell
14%
Oncogene
14%
Endothelial Cell
14%
Antiangiogenic
14%
Solid Malignant Neoplasm
14%
Vascularity
14%
Clinical Study
14%
Plasminogen Activator Inhibitor-1
14%
Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
100%
Neoplasm
100%
Urokinase
100%
Urokinase Receptor
85%
Receptor
28%
Metastasis
28%
Clinical Study
14%
Antiangiogenic
14%
Plasminogen Activator Inhibitor 1
14%
Solid Malignant Neoplasm
14%
Neovascularization (Pathology)
14%